// App-Quantinova.ai

: Early Response with Ixekizumab Predicts Long-Term Outcomes up to 5 Years in Psoriasis by Unsupervised and Supervised Machine Learning Analyses

Researchers

Presenter

  • Alexander Egeberg

Principal Investigators

  • Carle Paul

  • Andrew Blauvelt

  • Richard B Warren

  • Gaia Gallo gallo_gaia@lilly.com

  • Yan Wang

  • Kyoungah See

  • Yun-Fei Chen

  • April W Armstrong

Medical Centers

  • oH:S Bispebjerg Hospital, Copenhagen, Denmark

  • Toulouse University Hospital, Toulouse, France

  • Oregon Medical Research Center, Portland, OR

  • The University of Manchester, Salford Royal NHS Foundation Trust, Manchester, UK

  • Eli Lilly and Company, Indianapolis, IN

  • Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA

Locations

  • United States

  • United Kingdom

  • Denmark

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • LY2439821

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved